Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation
An. bras. dermatol
;
95(4): 473-476, July-Aug. 2020. graf
Artículo
en Inglés
| LILACS, ColecionaSUS
| ID: biblio-1130913
ABSTRACT
Abstract Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Piperidinas
/
Pirimidinas
/
Pirroles
/
Terapia Ultravioleta
/
Vitíligo
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
An. bras. dermatol
Año:
2020
Tipo del documento:
Artículo
Institución/País de afiliación:
Pontifícia Universidade Católica do Paraná/BR
/
Private Rheumatology Clinic/BR
/
Universidade do Vale do Itajaí/BR
Similares
MEDLINE
...
LILACS
LIS